Abnormal uterine bleeding associated with hormonal contraception
Millions of women in the United States use some type of hormonal contraception: combination oral contraceptive pills (OCPs), progestin-only pills, medroxyprogesterone acetate injections, or subdermal levonorgestrel implants. Abnormal uterine bleeding is a common but rarely dangerous side effect of h...
Gespeichert in:
Veröffentlicht in: | American family physician 2002-05, Vol.65 (10), p.2073-2085 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2085 |
---|---|
container_issue | 10 |
container_start_page | 2073 |
container_title | American family physician |
container_volume | 65 |
creator | Schrager, Sarina |
description | Millions of women in the United States use some type of hormonal contraception: combination oral contraceptive pills (OCPs), progestin-only pills, medroxyprogesterone acetate injections, or subdermal levonorgestrel implants. Abnormal uterine bleeding is a common but rarely dangerous side effect of hormonal contraception. It is, however, a major cause for the discontinuation of hormonal contraception and the resultant occurrence of unplanned pregnancy. The evaluation of abnormal uterine bleeding in women who are using hormonal contraception includes an assessment of compliance, a thorough history and complete physical examination to exclude organic causes of bleeding, and a targeted laboratory evaluation. Pregnancy and the misuse of OCPs are frequent causes of abnormal uterine bleeding. Bleeding is common during the first three months of OCP use; counseling and reassurance are adequate during this time period. If bleeding persists beyond three months, it can be treated with supplemental estrogen and/or a nonsteroidal anti-inflammatory drug (NSAID). Other options are to change to an OCP with a higher estrogen content or to a different formulation (i.e., a low-dose OCP containing a different progestin). Management strategies for women with abnormal uterine bleeding who are using progestin-only contraceptive methods include counseling and reassurance, as well as the administration of supplemental estrogen and/or an NSAID during bleeding episodes. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_18492950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>122267171</sourcerecordid><originalsourceid>FETCH-LOGICAL-g290t-273288bbced98a84544d3cf66e7d81d9205aa784fb6e3e933ef248e35d87247f3</originalsourceid><addsrcrecordid>eNpd0E1LAzEQBuAcFFurf0EWD94Wskl2k9wsxS8oeFHwtuRjtk3ZTWqSRfz3BqwXYWB44WF4mTO0xBiTWlDxsUCXKR1K5G0jL9CiIZh1nHdLdL_WPsRJjdWcIToPlR4BrPO7SqUUjFMZbPXl8r7aFxd8kSb4HJWBY3bBX6HzQY0Jrk97hd4fH942z_X29ells97WOyJxrgmnRAitDVgplGAtY5aaoeuAW9FYSXCrFBds0B1QkJTCQJgA2lrBCeMDXaG737vHGD5nSLmfXDIwjspDmFPfCCaJbHGBt__gIcyx9E49oazhZUhBNyc06wlsf4xuUvG7_3sM_QEdn13Z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>234174172</pqid></control><display><type>article</type><title>Abnormal uterine bleeding associated with hormonal contraception</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Schrager, Sarina</creator><creatorcontrib>Schrager, Sarina</creatorcontrib><description>Millions of women in the United States use some type of hormonal contraception: combination oral contraceptive pills (OCPs), progestin-only pills, medroxyprogesterone acetate injections, or subdermal levonorgestrel implants. Abnormal uterine bleeding is a common but rarely dangerous side effect of hormonal contraception. It is, however, a major cause for the discontinuation of hormonal contraception and the resultant occurrence of unplanned pregnancy. The evaluation of abnormal uterine bleeding in women who are using hormonal contraception includes an assessment of compliance, a thorough history and complete physical examination to exclude organic causes of bleeding, and a targeted laboratory evaluation. Pregnancy and the misuse of OCPs are frequent causes of abnormal uterine bleeding. Bleeding is common during the first three months of OCP use; counseling and reassurance are adequate during this time period. If bleeding persists beyond three months, it can be treated with supplemental estrogen and/or a nonsteroidal anti-inflammatory drug (NSAID). Other options are to change to an OCP with a higher estrogen content or to a different formulation (i.e., a low-dose OCP containing a different progestin). Management strategies for women with abnormal uterine bleeding who are using progestin-only contraceptive methods include counseling and reassurance, as well as the administration of supplemental estrogen and/or an NSAID during bleeding episodes.</description><identifier>ISSN: 0002-838X</identifier><identifier>PMID: 12046776</identifier><identifier>CODEN: AFPYBF</identifier><language>eng</language><publisher>United States: American Academy of Family Physicians</publisher><subject>Birth control ; Contraceptive Agents, Female - adverse effects ; Contraceptives, Oral - adverse effects ; Contraceptives, Oral, Combined - adverse effects ; Contraceptives, Oral, Hormonal - adverse effects ; Female ; Hemorrhage ; Humans ; Levonorgestrel - adverse effects ; Prescription drugs ; Progestins - adverse effects ; Side effects ; Uterine Hemorrhage - chemically induced ; Uterine Hemorrhage - drug therapy ; Women</subject><ispartof>American family physician, 2002-05, Vol.65 (10), p.2073-2085</ispartof><rights>Copyright American Academy of Family Physicians May 15, 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12046776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schrager, Sarina</creatorcontrib><title>Abnormal uterine bleeding associated with hormonal contraception</title><title>American family physician</title><addtitle>Am Fam Physician</addtitle><description>Millions of women in the United States use some type of hormonal contraception: combination oral contraceptive pills (OCPs), progestin-only pills, medroxyprogesterone acetate injections, or subdermal levonorgestrel implants. Abnormal uterine bleeding is a common but rarely dangerous side effect of hormonal contraception. It is, however, a major cause for the discontinuation of hormonal contraception and the resultant occurrence of unplanned pregnancy. The evaluation of abnormal uterine bleeding in women who are using hormonal contraception includes an assessment of compliance, a thorough history and complete physical examination to exclude organic causes of bleeding, and a targeted laboratory evaluation. Pregnancy and the misuse of OCPs are frequent causes of abnormal uterine bleeding. Bleeding is common during the first three months of OCP use; counseling and reassurance are adequate during this time period. If bleeding persists beyond three months, it can be treated with supplemental estrogen and/or a nonsteroidal anti-inflammatory drug (NSAID). Other options are to change to an OCP with a higher estrogen content or to a different formulation (i.e., a low-dose OCP containing a different progestin). Management strategies for women with abnormal uterine bleeding who are using progestin-only contraceptive methods include counseling and reassurance, as well as the administration of supplemental estrogen and/or an NSAID during bleeding episodes.</description><subject>Birth control</subject><subject>Contraceptive Agents, Female - adverse effects</subject><subject>Contraceptives, Oral - adverse effects</subject><subject>Contraceptives, Oral, Combined - adverse effects</subject><subject>Contraceptives, Oral, Hormonal - adverse effects</subject><subject>Female</subject><subject>Hemorrhage</subject><subject>Humans</subject><subject>Levonorgestrel - adverse effects</subject><subject>Prescription drugs</subject><subject>Progestins - adverse effects</subject><subject>Side effects</subject><subject>Uterine Hemorrhage - chemically induced</subject><subject>Uterine Hemorrhage - drug therapy</subject><subject>Women</subject><issn>0002-838X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0E1LAzEQBuAcFFurf0EWD94Wskl2k9wsxS8oeFHwtuRjtk3ZTWqSRfz3BqwXYWB44WF4mTO0xBiTWlDxsUCXKR1K5G0jL9CiIZh1nHdLdL_WPsRJjdWcIToPlR4BrPO7SqUUjFMZbPXl8r7aFxd8kSb4HJWBY3bBX6HzQY0Jrk97hd4fH942z_X29ells97WOyJxrgmnRAitDVgplGAtY5aaoeuAW9FYSXCrFBds0B1QkJTCQJgA2lrBCeMDXaG737vHGD5nSLmfXDIwjspDmFPfCCaJbHGBt__gIcyx9E49oazhZUhBNyc06wlsf4xuUvG7_3sM_QEdn13Z</recordid><startdate>20020515</startdate><enddate>20020515</enddate><creator>Schrager, Sarina</creator><general>American Academy of Family Physicians</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20020515</creationdate><title>Abnormal uterine bleeding associated with hormonal contraception</title><author>Schrager, Sarina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g290t-273288bbced98a84544d3cf66e7d81d9205aa784fb6e3e933ef248e35d87247f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Birth control</topic><topic>Contraceptive Agents, Female - adverse effects</topic><topic>Contraceptives, Oral - adverse effects</topic><topic>Contraceptives, Oral, Combined - adverse effects</topic><topic>Contraceptives, Oral, Hormonal - adverse effects</topic><topic>Female</topic><topic>Hemorrhage</topic><topic>Humans</topic><topic>Levonorgestrel - adverse effects</topic><topic>Prescription drugs</topic><topic>Progestins - adverse effects</topic><topic>Side effects</topic><topic>Uterine Hemorrhage - chemically induced</topic><topic>Uterine Hemorrhage - drug therapy</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schrager, Sarina</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>American family physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schrager, Sarina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abnormal uterine bleeding associated with hormonal contraception</atitle><jtitle>American family physician</jtitle><addtitle>Am Fam Physician</addtitle><date>2002-05-15</date><risdate>2002</risdate><volume>65</volume><issue>10</issue><spage>2073</spage><epage>2085</epage><pages>2073-2085</pages><issn>0002-838X</issn><coden>AFPYBF</coden><abstract>Millions of women in the United States use some type of hormonal contraception: combination oral contraceptive pills (OCPs), progestin-only pills, medroxyprogesterone acetate injections, or subdermal levonorgestrel implants. Abnormal uterine bleeding is a common but rarely dangerous side effect of hormonal contraception. It is, however, a major cause for the discontinuation of hormonal contraception and the resultant occurrence of unplanned pregnancy. The evaluation of abnormal uterine bleeding in women who are using hormonal contraception includes an assessment of compliance, a thorough history and complete physical examination to exclude organic causes of bleeding, and a targeted laboratory evaluation. Pregnancy and the misuse of OCPs are frequent causes of abnormal uterine bleeding. Bleeding is common during the first three months of OCP use; counseling and reassurance are adequate during this time period. If bleeding persists beyond three months, it can be treated with supplemental estrogen and/or a nonsteroidal anti-inflammatory drug (NSAID). Other options are to change to an OCP with a higher estrogen content or to a different formulation (i.e., a low-dose OCP containing a different progestin). Management strategies for women with abnormal uterine bleeding who are using progestin-only contraceptive methods include counseling and reassurance, as well as the administration of supplemental estrogen and/or an NSAID during bleeding episodes.</abstract><cop>United States</cop><pub>American Academy of Family Physicians</pub><pmid>12046776</pmid><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-838X |
ispartof | American family physician, 2002-05, Vol.65 (10), p.2073-2085 |
issn | 0002-838X |
language | eng |
recordid | cdi_proquest_miscellaneous_18492950 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
subjects | Birth control Contraceptive Agents, Female - adverse effects Contraceptives, Oral - adverse effects Contraceptives, Oral, Combined - adverse effects Contraceptives, Oral, Hormonal - adverse effects Female Hemorrhage Humans Levonorgestrel - adverse effects Prescription drugs Progestins - adverse effects Side effects Uterine Hemorrhage - chemically induced Uterine Hemorrhage - drug therapy Women |
title | Abnormal uterine bleeding associated with hormonal contraception |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A39%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abnormal%20uterine%20bleeding%20associated%20with%20hormonal%20contraception&rft.jtitle=American%20family%20physician&rft.au=Schrager,%20Sarina&rft.date=2002-05-15&rft.volume=65&rft.issue=10&rft.spage=2073&rft.epage=2085&rft.pages=2073-2085&rft.issn=0002-838X&rft.coden=AFPYBF&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E122267171%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=234174172&rft_id=info:pmid/12046776&rfr_iscdi=true |